Syndax Pharmaceuticals, Inc.
SNDX
$20.16
-$0.25-1.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 208.06M | 163.24M | 102.19M | 68.82M | 43.72M |
| Total Other Revenue | 9.36M | 9.36M | 9.36M | 9.36M | -- |
| Total Revenue | 217.42M | 172.60M | 111.55M | 78.18M | 43.72M |
| Cost of Revenue | 205.87M | 204.12M | 189.13M | 201.72M | 186.87M |
| Gross Profit | 11.56M | -31.52M | -77.58M | -123.54M | -143.14M |
| SG&A Expenses | 176.64M | 180.08M | 167.74M | 153.93M | 139.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 441.35M | 445.84M | 418.51M | 417.29M | 387.69M |
| Operating Income | -223.93M | -273.24M | -306.95M | -339.11M | -343.97M |
| Income Before Tax | -243.65M | -285.82M | -311.88M | -335.29M | -331.50M |
| Income Tax Expenses | -400.00K | -400.00K | -300.00K | -300.00K | -300.00K |
| Earnings from Continuing Operations | -243.25 | -285.42 | -311.58 | -334.99 | -331.20 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -243.25M | -285.42M | -311.58M | -334.99M | -331.20M |
| EBIT | -223.93M | -273.24M | -306.95M | -339.11M | -343.97M |
| EBITDA | -223.92M | -273.23M | -306.95M | -339.10M | -343.96M |
| EPS Basic | -2.80 | -3.30 | -3.62 | -3.90 | -3.87 |
| Normalized Basic EPS | -1.75 | -2.06 | -2.26 | -2.44 | -2.42 |
| EPS Diluted | -2.80 | -3.30 | -3.62 | -3.90 | -3.87 |
| Normalized Diluted EPS | -1.75 | -2.06 | -2.26 | -2.44 | -2.42 |
| Average Basic Shares Outstanding | 348.57M | 346.49M | 344.92M | 343.73M | 342.67M |
| Average Diluted Shares Outstanding | 348.57M | 346.49M | 344.92M | 343.73M | 342.67M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |